Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Immunotherapy of Cancer

2132 - Pre-specified interim analysis of a randomized phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Date

22 Oct 2018

Session

Proffered paper session - Immunotherapy of Cancer

Presenters

Daine Hale

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

D.F. Hale1, E.A. Mittendorf2, T.A. Brown1, G.T. Clifton1, T.J. Vreeland3, J. Myers1, K. Peace1, D. Jackson1, J. Greene1, J. Holmes4, G.E. Peoples5

Author affiliations

  • 1 General Surgery, San Antonio Military Medical Center, 78234 - Fort Sam Houston/US
  • 2 Surgical oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Surgical oncology, MD Anderson Cancer Center, 77030-3721 - Houston/US
  • 4 Medical Oncology, Naval Medical Center San Diego, San Diego/US
  • 5 Metis Foundation, CVDP, 78205 - SAN ANTONIO/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2132

Background

HER2 low-expressing (LE) (IHC 1-2+, non-amplified) breast cancer (BCa) patients (pts) are not eligible for HER2-targeted therapies as confirmed in the recent NSABP B-47 trial. We have shown the HER2-derived nelipeptimut-S (E75) + GM-CSF (NeuVax) is safe, immunogenic, & acts synergistically with trastuzumab (Tz) in pre-clinical & pilot clinical studies. Here, we present the interim analysis (IA) of a multi-center, prospective, randomized, single-blinded, placebo-controlled phase 2b trial of Tz + NeuVax vs Tz to reduce recurrence in HER2 LE, node positive (NP) and/or triple negative BCa (TNBC) pts.

Methods

Pts were randomized to receive Tz & NeuVax (vaccine group; VG) or Tz + GM-CSF (control group; CG). All pts received 1 year of Tz per label. NeuVax or GM-CSF was given Q3wk x 6 starting with 3rd Tz dose, then boosted Q6mo x 4. Cardiac ejection fraction (EF) was measured at baseline and serially on study. Pre-specified IA was triggered 6 mo after last enrollment. Analyses populations were intention-to- treat (ITT) & modified ITT/safety (mITT/S) (pts receiving ≥1 dose of NeuVax or GM-CSF). The primary endpoint is disease-free survival (DFS) at 24 mo evaluated by log-rank.

Results

275 pts were enrolled (VG n = 136, CG n = 139). No significant clinicopathologic differences were seen between groups. There was no difference between groups in related local (p = 0.19) or systemic (p = 0.85) toxicities (no grade 4/5 events) or in EF pre- to post-treatment (p = 0.60). At a median follow-up of 19.4 mo, estimated (est) 24 mo DFS in the VG vs CG was 88.6% vs 82.5% in ITT (p = 0.26, HR = 0.67) and 89.3% vs 82.3% in mITT/S (p = 0.17, HR = 0.61). In NP pts, est 24mo DFS in ITT VG vs CG was 85.9% vs 80.2% (p = 0.38, HR = 0.71), but in TNBC pts, it was 91.1% vs 69.9% (p = 0.02, HR = 0.26).

Conclusions

NeuVax + Tz is safe without added cardiac toxicity compared to Tz alone. The pre-specified IA shows efficacy trends overall in favor of the NeuVax + Tz combination, but most importantly demonstrates a highly significant clinical benefit in TNBC pts, suggesting the need for a definitive Ph3 study in this underserved pt population.

Clinical trial identification

NCT01570036.

Legal entity responsible for the study

George E. Peoples; Cancer Insight, LLC.

Funding

Sellas Life Sciences Group.

Editorial Acknowledgement

Disclosure

G.E. Peoples: NeuVax inventor rights. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings